JP2009544760A - 酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用 - Google Patents
酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用 Download PDFInfo
- Publication number
- JP2009544760A JP2009544760A JP2009529458A JP2009529458A JP2009544760A JP 2009544760 A JP2009544760 A JP 2009544760A JP 2009529458 A JP2009529458 A JP 2009529458A JP 2009529458 A JP2009529458 A JP 2009529458A JP 2009544760 A JP2009544760 A JP 2009544760A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pichia
- cell
- cells
- mucin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 34
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 108090000623 proteins and genes Proteins 0.000 title description 83
- 102000004169 proteins and genes Human genes 0.000 title description 44
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 42
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 229
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 199
- 229920001184 polypeptide Polymers 0.000 claims description 188
- 210000004027 cell Anatomy 0.000 claims description 113
- 108010063954 Mucins Proteins 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 60
- 239000000427 antigen Substances 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 150000007523 nucleic acids Chemical class 0.000 claims description 49
- 102000004190 Enzymes Human genes 0.000 claims description 48
- 108090000790 Enzymes Proteins 0.000 claims description 48
- 230000004927 fusion Effects 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 47
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 32
- 241000235648 Pichia Species 0.000 claims description 30
- 239000002671 adjuvant Substances 0.000 claims description 29
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 28
- 108010054395 P-selectin ligand protein Proteins 0.000 claims description 27
- 241000235058 Komagataella pastoris Species 0.000 claims description 24
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 24
- 108060003951 Immunoglobulin Proteins 0.000 claims description 21
- 102000018358 immunoglobulin Human genes 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 12
- 210000005253 yeast cell Anatomy 0.000 claims description 10
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 8
- 102100023123 Mucin-16 Human genes 0.000 claims description 8
- 241000222122 Candida albicans Species 0.000 claims description 7
- 241000320412 Ogataea angusta Species 0.000 claims description 7
- 229940095731 candida albicans Drugs 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 101000623897 Homo sapiens Mucin-12 Proteins 0.000 claims description 6
- -1 MUC10 Proteins 0.000 claims description 6
- 102100023143 Mucin-12 Human genes 0.000 claims description 6
- 241001452677 Ogataea methanolica Species 0.000 claims description 6
- 102000012404 Orosomucoid Human genes 0.000 claims description 5
- 108010061952 Orosomucoid Proteins 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 241000351920 Aspergillus nidulans Species 0.000 claims description 4
- 241000151861 Barnettozyma salicaria Species 0.000 claims description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 241000489470 Ogataea trehalophila Species 0.000 claims description 4
- 241000826199 Ogataea wickerhamii Species 0.000 claims description 4
- 241000530350 Phaffomyces opuntiae Species 0.000 claims description 4
- 241000529953 Phaffomyces thermotolerans Species 0.000 claims description 4
- 241000235062 Pichia membranifaciens Species 0.000 claims description 4
- 101000623900 Homo sapiens Mucin-13 Proteins 0.000 claims description 3
- 101000623905 Homo sapiens Mucin-15 Proteins 0.000 claims description 3
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 claims description 3
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 3
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims description 3
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 claims description 3
- 102100023124 Mucin-13 Human genes 0.000 claims description 3
- 102100023128 Mucin-15 Human genes 0.000 claims description 3
- 102100023125 Mucin-17 Human genes 0.000 claims description 3
- 102100034263 Mucin-2 Human genes 0.000 claims description 3
- 102100022693 Mucin-4 Human genes 0.000 claims description 3
- 102100022493 Mucin-6 Human genes 0.000 claims description 3
- 108010046220 N-Acetylgalactosaminyltransferases Proteins 0.000 claims description 3
- 102000007524 N-Acetylgalactosaminyltransferases Human genes 0.000 claims description 3
- 241001105191 Trichodes Species 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
- QIGJYVCQYDKYDW-SDOYDPJRSA-N alpha-D-galactosyl-(1->3)-D-galactose Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 60
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract description 57
- 238000006206 glycosylation reaction Methods 0.000 abstract description 28
- 230000013595 glycosylation Effects 0.000 abstract description 26
- 241000233866 Fungi Species 0.000 abstract description 13
- 241000206602 Eukaryota Species 0.000 abstract description 11
- 241000282412 Homo Species 0.000 abstract description 9
- 238000012545 processing Methods 0.000 abstract description 9
- 230000037361 pathway Effects 0.000 abstract description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 6
- 238000006911 enzymatic reaction Methods 0.000 abstract description 2
- 102000015728 Mucins Human genes 0.000 description 62
- 108020001507 fusion proteins Proteins 0.000 description 59
- 102000037865 fusion proteins Human genes 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 43
- 239000013598 vector Substances 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 102000002572 Alpha-Globulins Human genes 0.000 description 27
- 108010068307 Alpha-Globulins Proteins 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 23
- 229960005486 vaccine Drugs 0.000 description 22
- 239000013604 expression vector Substances 0.000 description 20
- 150000001720 carbohydrates Chemical class 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 108010087568 Mannosyltransferases Proteins 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 102000006722 Mannosyltransferases Human genes 0.000 description 15
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 15
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 15
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 15
- 108700023372 Glycosyltransferases Proteins 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 150000002482 oligosaccharides Chemical class 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 102000051366 Glycosyltransferases Human genes 0.000 description 12
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- 230000008685 targeting Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 8
- 102000001696 Mannosidases Human genes 0.000 description 8
- 108010054377 Mannosidases Proteins 0.000 description 8
- 108010058846 Ovalbumin Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000012707 chemical precursor Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 230000016784 immunoglobulin production Effects 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 7
- 210000002288 golgi apparatus Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229940051875 mucins Drugs 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 210000003463 organelle Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 230000004989 O-glycosylation Effects 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 238000005621 mannosylation reaction Methods 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000003259 recombinant expression Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 230000004988 N-glycosylation Effects 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
- 108010013050 Endo180 Proteins 0.000 description 4
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 4
- 108010031099 Mannose Receptor Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002121 endocytic effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000009851 immunogenic response Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 241000235649 Kluyveromyces Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 3
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 3
- 101710155891 Mucin-like protein Proteins 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 108010066816 Polypeptide N-acetylgalactosaminyltransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000005220 cytoplasmic tail Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000005931 immune cell recruitment Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003412 trans-golgi network Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000002086 C-type lectin-like Human genes 0.000 description 2
- 108050009406 C-type lectin-like Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010055629 Glucosyltransferases Proteins 0.000 description 2
- 102000000340 Glucosyltransferases Human genes 0.000 description 2
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 108050005077 Haptoglobin Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 101150053531 MNN1 gene Proteins 0.000 description 2
- DINOPBPYOCMGGD-VEDJBHDQSA-N Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 DINOPBPYOCMGGD-VEDJBHDQSA-N 0.000 description 2
- 101000761989 Mus musculus CD209 antigen-like protein A Proteins 0.000 description 2
- OSKIPPQETUTOMW-YHLOVPAPSA-N N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2R,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxy-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 OSKIPPQETUTOMW-YHLOVPAPSA-N 0.000 description 2
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 108010043045 Phospholipase A2 Receptors Proteins 0.000 description 2
- 102000004050 Phospholipase A2 Receptors Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100028688 Putative glycosylation-dependent cell adhesion molecule 1 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101100181264 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KTR6 gene Proteins 0.000 description 2
- 101100184479 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MNN4 gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108700027479 Syntex adjuvant formulation Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 2
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000009655 industrial fermentation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HMQPEDMEOBLSQB-UHFFFAOYSA-N n-[2,5-dihydroxy-6-(hydroxymethyl)-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide Chemical compound CC(=O)NC1C(O)OC(CO)C(O)C1OC1C(O)C(O)C(O)C(CO)O1 HMQPEDMEOBLSQB-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 108010012704 sulfated glycoprotein p50 Proteins 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 1
- 101710186701 Alpha-1-acid glycoprotein 1 Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101100130886 Candida albicans (strain SC5314 / ATCC MYA-2876) MNT1 gene Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100039847 Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102100021700 Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 230000025545 Golgi localization Effects 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000887519 Homo sapiens Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 Proteins 0.000 description 1
- 101000896564 Homo sapiens Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000170280 Kluyveromyces sp. Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 241001068914 Melicope knudsenii Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- REDMNGDGDYFZRE-WKWISIMFSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@H](N)C(O)=O REDMNGDGDYFZRE-WKWISIMFSA-N 0.000 description 1
- 230000010631 Opioid Receptor Interactions Effects 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 101100454113 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KRE2 gene Proteins 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- LFTYTUAZOPRMMI-NESSUJCYSA-N UDP-N-acetyl-alpha-D-galactosamine Chemical compound O1[C@H](CO)[C@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-NESSUJCYSA-N 0.000 description 1
- 108010090473 UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 102100023634 Zona pellucida sperm-binding protein 3 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002337 anti-port Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010288 cervix melanoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150097231 eg gene Proteins 0.000 description 1
- 108010043837 egg surface sperm receptor Proteins 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000030583 endoplasmic reticulum localization Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000167 fungal chromosome Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 108700004813 glycosylated insulin Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 108091005446 macrophage receptors Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000020801 protein mannosylation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 150000004043 trisaccharides Chemical group 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、下等真核生物における糖タンパク質の産生及びタンパク質のグリコシル化の工学の分野、具体的には発現されるオリゴマンノース又はヒト化O−グリカンを有する酵母における糖タンパク質の産生の分野に関する。本発明は、更に、ペプチド鎖におけるセリン又はスレオニンへのN−アセチルガラクトサミンの転移に関与する酵素をコードする遺伝子を含む新規な宿主細胞と、特に治療剤として有用な糖タンパク質の産生とに関する。
治療用ヒト組換えタンパク質を産生することの可能性によって、種々の異なる疾患の患者の治療に大きな変革がもたらされてきた。幾つかのタンパク質(例えばグリコシル化されないインスリン)は、原核生物の宿主(例えば大腸菌)内に産生され得る。大部分の治療用タンパク質は、ペプチド配列内の特異的なアミノ酸への糖残基の付加によって修飾されることを必要とする。このグリコシル化は、タンパク質の正確な折り畳み、長い循環半減期、そして多くの場合タンパク質の最適な活性のために必要であり得る。現在、グリコシル化タンパク質は、治療用タンパク質の世界的な年間売上高の60%以上を担っている。哺乳類細胞は、ヒト様グリコシル化を伴うタンパク質を産生し得るが、グリコシル化異種産物形成に関する低生産性等の他の短所、及びウィルス汚染のリスクを有する。酵母細胞は、産業的な発酵のための確固たる生物であり、明確な培地中で高密度に培養され得る。
酵母において産生される糖タンパク質におけるN−結合マンノース及びO−結合マンノースの存在は、ワクチンの抗原に結合する場合、例えばウィルス、細菌及び癌細胞に存在する抗原に対して高められた免疫応答を引き起こす目的で免疫系の特異的なターゲティングのために利用され得る。これは、ヒト免疫系の特定の細胞におけるマンノース結合レセプターの存在によって達成され得る。マンノース結合レセプターとしては、マクロファージマンノースレセプター(MMR;CD206)が挙げられ、それは、システインリッチ(CR)ドメイン、フィブロネクチンタイプIIリピート(FNII)を含むドメイン及び複数のC型レクチン様糖認識ドメイン(CTLD)を含む細胞外領域、膜貫通領域及び短い細胞質尾部から構成される4つの哺乳類エンドサイトーシスレセプターのファミリーの内で最初に発見されたものであった。前記ファミリーとしてはまた、ホスホリパーゼA2レセプター、Endo180及びDEC205(CD205)が挙げられるが、MMR及びEndo180だけは、Ca2+に依存する方法で炭水化物に結合するする能力を有する。それらは全てI型タンパク質であって、複数のCTLDを含む。細胞間接着分子(ICAM)−3と相互作用するレセプターとして最初に記述され、それ故に樹状細胞特異的ICAM−3−グラッビング非インテグリン(dendritic cell−specific ICAM−3−grabbing nonintegrin;DC―SIGN;CD209)と名づけられた、高マンノース構造を結合する別のレセプターは、樹状細胞におけるII型タンパク質である。MMR及びDC−SIGNの両方は、MHCの発現及びその後のT細胞の活性化をもたらすエンドサイトーシス経路内に内在性抗原を導く能力を有する。MMR又はDC−SIGNに特異的な抗体は、腫瘍関連抗原に結合すると、両MHCクラスI及びII制限T細胞反応を刺激することが示されている。更に近年、O−グリカン又はN−グリカンのいずれか或いは両方を含むオボアルブミン(OVA)は、酵母(Pichia pastoris)において発現される場合、OVA特異的CD4+T細胞分裂反応の誘導に対して非マンノシル化OVAよりも効力があったことが示された。
本明細書に記載される方法及び組換え下等真核生物株は、「ヒト化糖タンパク質」を作製するために使用される。組換え下等真核生物は、高マンノース構造の産生に関与する1つ以上の酵素を発現し得ない下等真核生物を設計してヒト様糖を産生するために必要とされる酵素を発現させることによって作製される。本明細書で用いられる下等真核生物は、単細胞菌類又は糸状菌類である。本明細書で用いられる「ヒト化糖タンパク質」とは、それに結合した、ヒトムチン及びムチン様タンパク質(下記参照)に一般に発現されるO−グリカン、及び合成中間体(それも有用であり、in vitroで更に操作され得る)を有するタンパク質をいう。これは、ヒトムチン又はムチン様タンパク質、即ちタンパク質がグリコシル化される部位の生物に存在する条件下で最適活性を有するように選択される酵素におけるO−グリカンの産生に関与する種々のグリコシルトランスフェラーゼのクローニングによって、若しくは活性が要求される細胞小器官に酵素を標的化することによって達成される。更に、幾つかの酵母内在性マンノシルトランスフェラーゼは、挿入されたグリコシルトランスフェラーゼと内在性のグリコシルトランスフェラーゼとの間の競合を回避するためにノックアウト又はノックダウンされ得る。本発明はまた、酵母において産生される糖タンパク質において発現される多くのマンノース残基がヒト免疫系におけるマンノースレセプターの標的化に有用である方法を提供する。従って、別の一態様において、本発明はまた、マンノシル化、N−結合又はO−結合のいずれか、或いはその両方の融合タンパク質も提供するものである。
ヒト化糖タンパク質の産生
好ましくは、ムチン又はムチン様型融合タンパク質に位置する可能なN−グリカンへの免疫原性応答を防止するために、N−グリカン高マンノース構造の作製に関与する1つ以上の酵素を発現しない真核生物菌株が用いられる。これらの菌株は、設計され得るか、若しくはPichia pastorisのハイパーマンノシル化−マイナス(OCH1)突然変異体等の、酵母において既に記載された多くの突然変異体の内の1つであり得る。
また、N−結合オリゴマンノース構造又はO−結合オリゴマンノース構造或いはその両方を担持する融合タンパク質は本発明に含まれる。本発明の融合タンパク質は、特異性抗原に対する反応を高める際に有用である。これは、ワクチン抗原へのマンノシル化融合タンパク質の結合によって達成され得る。前記融合タンパク質は、マンノース結合レセプターに対する結合によってマクロファージ及び樹状細胞にワクチン抗原を標的化し、これによって各種ワクチン成分の免疫原性を増大させる。従って、本発明のマンノシル化融合タンパク質はワクチンのアジュバントとして有用である。かかるターゲティングはまた、各種の画像化の応用にも有用である。
また、本発明のMan−融合タンパク質は、ワクチンのアジュバントとしても有用である。本発明のワクチンは、アジュバントポリペプチドが欠如している他のワクチンよりも優れた免疫予防的性質及び免疫療法的性質を有する。ムチン−Ig融合タンパク質を含むワクチンは、免疫原性、安全性、耐容性及び有効性が高められる。例えば、本発明のワクチンの高められた免疫原性は、抗体の産生及び/又は分泌、T細胞の活性化及び拡大並びにサイトカイン発現(例えばインターロイキンの産生)等の免疫応答の刺激で測定される場合、比較の非アジュバントポリペプチドを含有するワクチンよりも1.5倍、2倍、3倍、5倍、10倍、20倍、50倍、100倍以上大きい。
本発明は、細胞における抗体の産生及び/又は分泌を増大又は刺激する方法を提供するものである。前記細胞はB細胞等の抗体産生細胞である。或いは、前記細胞は、T細胞(Th及びTc)、マクロファージ、樹状細胞等の、B細胞による抗体産生を増大させる細胞である。
本発明は、免疫細胞(例えばB細胞又はT細胞)を活性化又は刺激する方法を提供するものである。T細胞の活性化は、カルシウム仲介細胞内cGMPの増加、又はIL−2のための細胞表面レセプターの増加によって定義される、例えば、T細胞活性化の増加は、ワクチンがない場合よりも、ワクチンをT細胞に接触させた後のカルシウム仲介細胞内cGMP及び/又はIL−2レセプターが増加することを特徴とする。細胞内cGMPは、例えば、市販の試験キットを使用して、競合イムノアッセイ又はシンチレーション近接アッセイによって測定される。細胞表面IL−2レセプターは、例えば、PC61抗体等のIL−2レセプター抗体への結合を決定することによって測定される。また、免疫細胞活性化は、当該技術分野で周知の方法によって、B細胞増殖活性、ポリクローナル免疫グロブリン(Ig)産生及び抗原特異性抗体産生を測定することによって決定することができる。
本発明の融合ペプチドは、医薬組成物において調製することができる。これらの組成物は、上記の物質の内の1つに加えて、当業者に周知の薬学的に許容される賦形剤、担体、緩衝液、安定剤又はその他の材料を含むことができる。かかる材料は、無毒性である必要があり、活性成分の有効性を妨げてはならない。担体又は他の材料の明確な性質は、投与経路(例えば経口経路、静脈内経路、皮膚経路又は皮下経路、経鼻経路、筋肉内経路、腹腔内経路或いは貼付剤経路)に依存し得る。
ムチン様タンパク質の細胞外の部分(P−セレクチン糖タンパク質リガンド−1)を含む融合タンパク質のためのcDNA配列、或いはα1−酸糖タンパク質のための翻訳停止及びマウスIgG2bのFc部分を除くコード配列全体を、ピキアパストリス(P.pastoris)のための発現ベクターにサブクローニングする。PSGL−1/mIgG2bは主にO−グリカンを担持するが、一方でAGP/mIgG2bはN−グリコシル化されるだけである。酵母はトランスフェクションされ、選択薬物としてZeocinを使用して安定的なトランスフェクタントを選択する。分泌された融合タンパク質は、アフィニティクロマトグラフィー及びゲル濾過によって精製され、そしてβ−除去及びPNGase F消化によってそれぞれO−グリカン及びN−グリカンが放出される。放出された糖類は、質量分析法によって特徴が記述される。構造キャラクタリゼーションの焦点はO−グリカンにあるが、それはO−グリカンが以前には詳細な特徴が記述されていないからであり、そして我々の長期的な目標が、ピキアパストリス(P.pastoris)を設計してよりヒト様のO−グリカンを合成することにあるからである。
野生型ピキア属において産生されるPSGL−1及びAGPの免疫グロブリン融合タンパク質を、実験において精製及び使用し、マクロファージレセプター結合を評価する。この目的で、単離されたマクロファージ及び樹状細胞を使用して、マンノシル化融合タンパク質の、蛍光ナノ粒子とマイクロ粒子とタンパク質(即ち緑色蛍光タンパク質)とのトレーサ粒子及びタンパク質へ共有結合後の取り込みを促進する能力を評価する。同様に、モデルタンパク質の免疫原性に対するマンノシル化の効果を、マンノシル化融合タンパク質へのその共役、抗原提示細胞(MO及びDC)による取り込み、及び精製CD4+及びCD8+Tリンパ球群による次のインキュベーション後に、テストする。同様に、血清に由来するマンナン結合レクチン(MBL)を、ピキア属において産生される各種の融合タンパク質に結合する能力に関してテストする。我々は、これにより、MBLへの結合に重要なマンノース構造(N−結合又はO−結合)はどれかについてのなんらかの情報を得るものと考える。
次のステップは、ヒト化O−グリカンレパートリーを有するPSGL−1/mIgG2Bを発現することである。この目的で、我々は、1つ又は幾つかのUDP−N−アセチル−D−ガラクトサミニド:ポリペプチドN―アセチルガラクトサミニルトランスフェラーゼ(ppGalNAc−Ts)を共発現し、それは、ペプチド配列特異的な方法でペプチド鎖におけるアミノ酸のセリン又はスレオニンにN−アセチルガラクトサミン残基を付加する酵素である。最初に、我々は、酵素の天然形態を発現する。これが結果として誤ったER/ゴルジ局在化になる場合、我々は、ppGalNAc−Tの触媒ドメインが、第1のマンノース残基をペプチド鎖に結合する酵母特異的マンノシルトランスフェラーゼの膜貫通領域に融合された酵素のキメラ形態を発現させる。これが機能しない場合、ピキア属の他のII型タンパク質からの膜貫通シグナル配列を試みる。更に、我々は、おそらく、ピキア属O−グリカンの生合成に関与する各種のマンノシルトランスフェラーゼの発現を非発現化することを必要とする。相同組換えによる完全な非発現化が致死的である場合、我々はsiRNA技術を用いて部分的な遺伝子の非発現化を達成することを試みる。内在性マンノシルトランスフェラーゼの非発現化は、酵母生存度を維持して、マンノース残基の代わりのGalNAc残基の移入に有利となるのに十分な平衡状態を変えることができる。更に、ピキア属におけるヒト様O−グリカンレパートリーを得るために、それはまた、ゴルジ膜を通してUDP−GalNAcを取得する輸送体を発現するのに必要であり得る。ヒトグリコシルトランスフェラーゼを担持する突然変異体酵母コロニーは、レクチンブロットによって同定する。要するに、成長する酵母コロニーのレプリカは、分泌されたPSGL−1/mIgG融合タンパク質を捕捉するためにニトロセルロース膜でそれらをおおうことによって作製する。洗浄後、膜を、既知の炭水化物特異性のレクチンでプローブする。PSGL−1 Ig融合における所望のグリカンを有する酵母のコロニーは更に拡大し、融合タンパク質によって担持されるO−グリカンレパートリーはその精製後に構造的に特徴が記述される。組換えタンパク質は、上記の通りに精製されて、構造的に特徴が記述される。開始するグリコシル化ステップが成功である場合、最も内部の糖は、治療能のエピトープが作製され得るように、更なるグリコシルトランスフェラーゼ遺伝子を導入することによって構築することができる。
他の実施形態
本発明は、その詳細な説明に関連して記載されたが、上記記述は、添付の請求の範囲によって定義される本発明の範囲を例示することを意図するものであって、限定することを意図するものではない。他の態様、利点及び改変は、以下の請求項の範囲内である。
Claims (19)
- 第2のポリペプチドに作動可能に結合する第1のポリペプチドを含む融合ポリペプチドであって、該第1のポリペプチドがマンノシル化され、該第2のポリペプチドが免疫グロブリンポリペプチドの少なくとも1つの領域を含む、融合ポリペプチド。
- 前記第1のポリペプチドがムチンポリペプチドである、請求項1に記載の融合ポリペプチド。
- 前記ムチンが、PSGL−1、MUC1、MUC2、MUC3a、MUC3b、MUC4、MUC5a、MUC5b、MUC5c、MUC6、MUC10、MUC11、MUC12、MUC13、MUC15、MUC16、MUC17、CD34、CD43、CD45、CD96、GlyCAM−1、MAdCAM又はそのフラグメントからなる群から選択される、請求項2に記載の融合ポリペプチド。
- 前記ムチンポリペプチドがP−セレクチン糖タンパク質リガンド−1の少なくとも1つの領域を含む、請求項2に記載の融合ポリペプチド。
- 前記ムチンポリペプチドがP−セレクチン糖タンパク質リガンド−1の細胞外の部分を含む、請求項2に記載の融合ポリペプチド。
- 前記第1のポリペプチドがアルファ糖タンパク質ポリペプチドである、請求項1に記載の融合ポリペプチド。
- 前記第1のポリペプチドがα−1−酸糖タンパク質の少なくとも1つの領域を含む、請求項1に記載の融合ポリペプチド。
- 前記第2のポリペプチドが重鎖の免疫グロブリンポリペプチドの領域を含む、請求項1に記載の融合ポリペプチド。
- 前記第2のポリペプチドが免疫グロブリン重鎖のFc領域を含む、請求項1に記載の融合ポリペプチド。
- 請求項1に記載の融合ポリペプチドを含むアジュバント組成物。
- Galα1,3Galエピトープを担持するポリペプチドを更に含む請求項10に記載のアジュバント組成物。
- ワクチン摂取を必要とする被験体にワクチン接種する方法であって、請求項10又は11に記載のアジュバント及び抗原を含む組成物を該被験体に投与することを含む、方法。
- 請求項1に記載の融合ポリペプチドを産生するように遺伝子組み換えされた、酵母細胞。
- 前記細胞がPichia pastoris、Pichia finlandica、Pichia trehalophila、Pichia koclamae、Pichia membranaefaciens、Pichia opuntiae、Pichia thermotolerans、Pichia salictaria、Pichia guercuum、Pichia pyperi、Pichia stiptis、Pichia methanolica、ピキア種、Saccharomyces cerevisiae、サッカロミセス種、Hansenula polymorpha、クルイヴェロマイシス種、Candida albicans、Aspergillus nidulans又はTrichoderma reeseiである、請求項13に記載の酵母細胞。
- O−結合グリカンを有することを特徴とするヒト様糖タンパク質を産生する、遺伝子組み換えされた下等真核細胞。
- 前記細胞がN−アセチルガラクトサミニルトランスフェラーゼを発現する、請求項15に記載の細胞。
- N−アセチルガラクトサミニルトランスフェラーゼをコードする核酸分子を含む、ヒト様糖タンパク質を産生する組換え下等真核細胞。
- 前記細胞がPichia pastoris、Pichia finlandica、Pichia trehalophila、Pichia koclamae、Pichia membranaefaciens、Pichia opuntiae、Pichia thermotolerans、Pichia salictaria、Pichia guercuum、Pichia pyperi、Pichia stiptis、Pichia methanolica、ピキア種、Saccharomyces cerevisiae、サッカロミセス種、Hansenula Polymorpha、クルイヴェロマイシス種、Candida albicans、Aspergillus nidulans又はTrichoderma reeseiである、請求項15又は17に記載の細胞。
- 前記細胞が、高マンノース構造の産生に関与する1つ以上の酵素を発現しない、請求項15又は17に記載の細胞。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76163206P | 2006-01-23 | 2006-01-23 | |
PCT/IB2007/004164 WO2007087420A2 (en) | 2006-01-23 | 2007-01-23 | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009544760A true JP2009544760A (ja) | 2009-12-17 |
JP2009544760A5 JP2009544760A5 (ja) | 2011-01-13 |
Family
ID=38309861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009529458A Pending JP2009544760A (ja) | 2006-01-23 | 2007-01-23 | 酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070184063A1 (ja) |
EP (1) | EP2021366A2 (ja) |
JP (1) | JP2009544760A (ja) |
AU (1) | AU2007208218A1 (ja) |
CA (1) | CA2637947A1 (ja) |
WO (1) | WO2007087420A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014524445A (ja) * | 2011-08-17 | 2014-09-22 | グローブイミューン,インコーポレイテッド | 酵母−muc1免疫療法用組成物およびその使用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2637947A1 (en) * | 2006-01-23 | 2007-07-23 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
PL2148691T3 (pl) | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
WO2011008565A1 (en) | 2009-06-29 | 2011-01-20 | Synthetic Genomics, Inc. | Acyl-acp thioesterase genes and uses therefor |
RU2604811C2 (ru) | 2010-05-27 | 2016-12-10 | Мерк Шарп Энд Домэ Корп. | Способ получения антител с улучшенными свойствами |
US9328170B2 (en) | 2011-05-25 | 2016-05-03 | Merck Sharp & Dohme Corp. | Method for preparing Fc containing polypeptides having improved properties |
US10323081B2 (en) | 2011-07-06 | 2019-06-18 | Genmag A/S | Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains |
CN104800838B (zh) * | 2015-04-14 | 2018-01-09 | 深圳市中联生物科技开发有限公司 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
CN105950647A (zh) * | 2016-05-16 | 2016-09-21 | 浙江理工大学 | 一种高效表达与制备外分泌型人源ca125的方法 |
US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005530493A (ja) * | 2002-04-22 | 2005-10-13 | レコファーマ アーベー | ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法 |
JP2005532793A (ja) * | 2002-04-22 | 2005-11-04 | レコファーマ アーベー | 微生物付着を阻害するための融合ポリペプチドおよび方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3618637A (en) * | 1970-02-04 | 1971-11-09 | Deseret Pharma | Rotary mixing valve |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6124267A (en) * | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US5516964A (en) * | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
US7399847B1 (en) * | 1996-11-25 | 2008-07-15 | The General Hospital Corporation | Nucleic acids encoding artificial P-selectin ligands |
US6689605B1 (en) * | 1997-05-22 | 2004-02-10 | Uab Research Foundation | Controlling immune response to specific antigens |
JP4421894B2 (ja) * | 2001-07-20 | 2010-02-24 | アブソーバー アクチボラゲット | 血液型抗原融合ポリペプチドおよびその使用方法 |
JP2008517073A (ja) * | 2004-10-14 | 2008-05-22 | レコファーマ アーベー | Helicobacterpylori付着およびHelicobacterpylori感染を阻害するための組成物ならびに方法 |
CA2637947A1 (en) * | 2006-01-23 | 2007-07-23 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
-
2007
- 2007-01-23 CA CA002637947A patent/CA2637947A1/en not_active Abandoned
- 2007-01-23 WO PCT/IB2007/004164 patent/WO2007087420A2/en active Application Filing
- 2007-01-23 US US11/626,156 patent/US20070184063A1/en not_active Abandoned
- 2007-01-23 AU AU2007208218A patent/AU2007208218A1/en not_active Abandoned
- 2007-01-23 EP EP07849046A patent/EP2021366A2/en not_active Ceased
- 2007-01-23 JP JP2009529458A patent/JP2009544760A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005530493A (ja) * | 2002-04-22 | 2005-10-13 | レコファーマ アーベー | ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法 |
JP2005532793A (ja) * | 2002-04-22 | 2005-11-04 | レコファーマ アーベー | 微生物付着を阻害するための融合ポリペプチドおよび方法 |
Non-Patent Citations (3)
Title |
---|
JPN5009013407; LAM JENNIFER S: JOURNAL OF IMMUNOLOGY V175 N11, 20051201, P7496-7503 * |
JPN6012048201; Bioprocess Int.,Vol.1,No.4(2003)p.44-53 * |
JPN7012001525; Glycobiology,Vol.14,No.1(2004)p.27-37 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014524445A (ja) * | 2011-08-17 | 2014-09-22 | グローブイミューン,インコーポレイテッド | 酵母−muc1免疫療法用組成物およびその使用 |
US9533031B2 (en) | 2011-08-17 | 2017-01-03 | Globeimmune, Inc. | Yeast-MUC1 immunotherapeutic compositions and uses thereof |
JP2017122120A (ja) * | 2011-08-17 | 2017-07-13 | グローブイミューン,インコーポレイテッド | 酵母−muc1免疫療法用組成物およびその使用 |
US10188714B2 (en) | 2011-08-17 | 2019-01-29 | Globeimmune, Inc. | Yeast-MUC1 immunotherapeutic compositions and uses thereof |
JP2019194261A (ja) * | 2011-08-17 | 2019-11-07 | グローブイミューン,インコーポレイテッド | 酵母−muc1免疫療法用組成物およびその使用 |
US11065318B2 (en) | 2011-08-17 | 2021-07-20 | Globeimmune, Inc. | Yeast-MUC1 immunotherapeutic compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20070184063A1 (en) | 2007-08-09 |
CA2637947A1 (en) | 2007-07-23 |
WO2007087420A8 (en) | 2008-09-25 |
WO2007087420A3 (en) | 2008-12-31 |
WO2007087420A2 (en) | 2007-08-02 |
AU2007208218A1 (en) | 2007-08-02 |
EP2021366A2 (en) | 2009-02-11 |
WO2007087420A9 (en) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009544760A (ja) | 酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用 | |
US20090181041A1 (en) | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof | |
CN102648280B (zh) | 生产含有特定聚糖结构之分子的方法 | |
JP6017439B2 (ja) | N−アセチルグルコサミニルトランスフェラーゼ活性を有する融合酵素 | |
US20140286946A1 (en) | Method for preparing antibodies having improved properties | |
JP2015120754A (ja) | 血清アミロイドp誘導体並びに同誘導体の製造及び使用 | |
KR20120084734A (ko) | 숙주 세포 항원에 대한 항체에 대한 검출가능한 교차 결합 활성이 결여된 단백질을 피키아 파스토리스에서 생산하는 방법 | |
JP2015502144A (ja) | Alg3の発現を欠損したピキア・パストリス(Pichiapastris)株中のN−グリカン占有率を増加させ、ハイブリッドN−グリカンの産生を低減させる方法 | |
WO2019234021A1 (en) | Glycoengineered monoclonal antibody | |
JP2016518114A (ja) | オリゴ糖組成物、糖タンパク質および原核生物においてそれらを産生する方法 | |
CA2537161C (en) | Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris) | |
US20220111027A1 (en) | Glyco-engineered immunization antigens | |
US20130330340A1 (en) | Production of n- and o-sialylated tnfrii-fc fusion protein in yeast | |
US9416389B2 (en) | Methods for reducing mannosyltransferase activity in lower eukaryotes | |
CN111770991A (zh) | 糖工程 | |
EP1984504A2 (en) | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof | |
US20220112535A1 (en) | Production of protein with humanized n-glycosylation in insect cells | |
WO2024105236A1 (en) | Recombinant production of protein having xylosylated n-glycans | |
US20200277641A1 (en) | Genetically engineered eukaryotic cells producing sialylated glycoproteins | |
WO2008142483A2 (en) | Vaccine compositions and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100122 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120719 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120912 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130221 |